|
|
|
| Effect of Ezetimibe on patients with progressive stroke |
| YANG Lan1 ZHAO Pingping2 ZHAO Jing1 WANG Juan1 WANG Xiaopeng1 |
1.Department of Neurology, the Second Hospital of Hebei Medical University, Hebei Province, Shijiazhuang 050000, China;
2.Department of Neurology, the Third Hospital of Shijiazhuang City, Hebei Province, Shijiazhuang 050000, China |
|
|
|
Abstract Objective To explore the effect of Ezetimibe on patients with progressive stroke. Methods A total of 423 patients with progressive stroke admitted to the Second Hospital of Hebei Medical University from January 2016 to December 2018 were selected as the research objects. They were divided into control (214 cases) and Ezetimibe group (209 cases) by random number table method. Control group was received basic treatment, and Ezetimibe group was received Ezetimibe treatment on the basis of control group and the course of treatment was 14 days. National institutes of health stroke scale (NIHSS) score, carotid plaque volume, interleukin-6 (IL-6), metallomatrix proteinase 9 (MMP-9), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triacylglycerol (TG), alanine aminotransferase (ALT) and total bilirubin (TBil) were compared between two groups before and after treatment. The self-care ability, home condition and death of two groups were compared after three months follow-up. Results Before treatment, there were no significant differences in NIHSS scores between two groups (P > 0.05). NIHSS scores in Ezetimibe group were lower than those in control group after treatment, and the differences were highly statistically significant (P < 0.01). There were no significant differences in self-care ability, home condition, and death rate between two groups after three months follow-up (P > 0.05). Before treatment, there were no significant differences in carotid plaque volume, IL-6, and MMP-9 levels between two groups (P > 0.05). After treatment, carotid plaque volume in two groups were smaller than those before treatment, and Ezetimibe group was smaller than control group, and the differences were statistically significant (P < 0.05). IL-6 and MMP-9 levels in two groups were lower than those before treatment, and Ezetimibe group was lower than control group, and the differences were statistically significant (P < 0.05). There were no significant differences in TG and HDL-C levels between two groups before and after treatment (P > 0.05). After treatment, the levels of TC and LDL-C in Ezetimibe group were lower than those before treatment, and Ezetimibe group was lower than control group, and the differences were statistically significant (P < 0.05). There were no significant differencea in ALT and TBil between two groups before and after treatment (P > 0.05). Conclusion Ezetimibe may be an effective drug for the treatment of progressive stroke.
|
|
|
|
|
|
[1] Denes A，Thornton P，Rothwell NJ，et al. Inflammation and brain injury：acute cerebral ischaemia，peripheral and central inflammation [J]. Brain Behav Immun，2010，24（5）：708-723.
[2] Tsivgoulis G，Saqqur M，Sharma VK，et al. Timing of Recanalization and Functional Recovery in Acute Ischemic Stroke [J]. J Stroke，2020，22（1）：130-140.
[3] Yang L，Zhao P，Zhao J，et al. Effects of ezetimibe and anticoagulant combined therapy on progressing stroke：a randomized，placebo-controlled study [J]. J Neurol，2016，263（12）：2438-2445.
[4] Morillo-Hernandez C，Lee JJ，English JC，et al. Retrospective outcome analysis of 25 alopecia areata patients treated with simvastatin/ezetimibe [J]. J Am Acad Dermatol，2019，81（3）：854-857.
[5] Lin YC，Lai TS，Wu HY，et al. Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease：A Systematic Review and Meta-Analysis [J]. Clin Pharmacol Ther，2020，108（4）：833-843.
[6] Colhoun HM，Leiter LA，Müller-Wieland D，et al. Effect of alirocumab on individuals with type 2 diabetes，high triglycerides，and low high-density lipoprotein cholesterol [J]. Cardiovasc Diabetol，2020，19（1）：14.
[7] Gencer B，Mach F，Murphy SA，et al. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction：A Prespecified Secondary Analysis From the FOURIER Trial [J]. JAMA Cardiol，2020，5（8）：1-6.
[8] Santos HO，Earnest CP，Tinsley GM，et al. Small dense low-density lipoprotein-cholesterol（sdLDL-C）：Analysis，effects on cardiovascular endpoints and dietary strategies [J]. Prog Cardiovasc Dis，2020，63（4）：503-509.
[9] 中华医学会神经病学分会，中华医学会神经病学分会，脑血管病学组，等.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志，2018，9（51）：666-682.
[10] Ouchi Y，Sasaki J，Arai H，et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older （EWTOPIA 75）：A Randomized，Controlled Trial [J]. Circulation，2019，140（12）：992-1003.
[11] Grundy SM，Stone NJ，Guideline Writing Committee for the 2018 Cholesterol Guidelines. 2018 Cholesterol Clinical Practice Guidelines：Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline [J]. Ann Intern Med，2019，170（11）：779-783.
[12] Allahyari A，Jernberg T，Hagstr?觟m E，et al. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction：a simulation study [J]. Eur Heart J，2020，41（40）：3900-3909.
[13] Qamar A，Giugliano RP，Bohula EA，et al. Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial [J]. J Am Coll Cardiol，2019，74（8）：1057-1068.
[14] Oh M，Kim H，Shin EW，et al. Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation [J]. BMC Cardiovasc Disord，2019，19（1）：201.
[15] Li D，McCaw ZR，Wei LJ，et al. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older [J]. JAMA Cardiol，2020，19（1）：201.
[16] Amarenco P，Kim JS，Labreuche J，et al. Benefit of Targeting a LDL （Low-Density Lipoprotein） Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke [J]. Stroke，2020，51（4）：1231-1239.
[17] Jia C，Malone HM，Keasey MP，et al. Blood Vitronectin Induces Detrimental Brain Interleukin-6 and Correlates With Outcomes After Stroke Only in Female Mice [J]. Stroke，2020，51（5）：1587-1595.
[18] Ziegler L，Frumento P，Wallén H，et al. The predictive role of interleukin 6 trans-signalling in middle-aged men and women at low-intermediate risk of cardiovascular events [J]. Eur J Prev Cardiol，2020，27（2）：122-129.
[19] Huehnchen P，Muenzfeld H，Boehmerle W，et al. Blockade of IL-6 signaling prevents paclitaxel-induced neuropathy in C57Bl/6 mice [J]. Cell Death Dis，2020，11（1）：45.
[20] Gupta M，Blumenthal C，Chatterjee S，et al. Novel emerging therapies in atherosclerosis targeting lipid metabol-ism [J]. Expert Opin Investig Drugs，2020，29（6）：611-622.
[21] Saba L，Saam T，J?覿ger HR，et al. Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications [J]. Lancet Neurol，2019，18（6）：559-572.
[22] Song P，Fang Z，Wang H，et al. Global and regional prevalence，burden，and risk factors for carotid atherosclerosis：a systematic review，meta-analysis，and modelling study [J]. Lancet Glob Health，2020，8（5）：e721-e729.
[23] Wen D，Du X，Nie SP，et al. Association between matrix metalloproteinase family gene polymorphisms and ischemic stroke：a meta-analysis [J]. Mol Neurobiol，2014， 50（3）：979-985.
[24] Zhong C，Yang J，Xu T，et al. Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke [J]. Neurology，2017，89（8）：805-812.
[25] Shimizu H，Tominaga T，Ogawa A，et al. Cilostazol for the prevention of acute progressing stroke：a multicenter，randomized controlled trial [J]. J Stroke Cerebrovasc Dis，2013，22（4）：449-456.
|
|
|
|
